Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II studyRichard C. Becker, Robert A. Harrington, David J. Moliterno et al.|The Lancet|2009Cited by 298
Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".Dean J. Kereiakes, Mauricio G. Cohen, E Fry et al.|PubMed|2000Cited by 43
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effectsDougal R. McClean, James Hanyok, Rafael F. Sequeira et al.|Journal of the American College of Cardiology|2002Cited by 36